APP
ARNA

Avantax Planning Partners’s Arena Pharmaceuticals Inc ARNA Stock Holding History

Avantax Planning Partners’s Portfolio ARNA Stock Details ARNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,000
Closed -$40K – 1646
2018
Q1 		$40K Buy
+1,000
New +$38.9K ﹤0.01% 572
2017
Q2 		– Sell
-1,000
Closed -$15K – 355
2017
Q1 		$15K Hold
1,000
– – ﹤0.01% 330
2016
Q4 		$14K Buy
+1,000
New +$15.5K ﹤0.01% 315

Other funds holding ARNA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Avantax Planning Partners's ARNA Position: Q2 2018 in Review

Avantax Planning Partners sold out of Arena Pharmaceuticals Inc (ARNA) in Q2 2018, closing a stake of 1,000 shares — an estimated $40K sold.

Avantax Planning Partners first reported a position in ARNA in Q4 2016 and held it in 3 quarters. The position peaked at $40K in Q1 2018. 165 funds tracked by Wall St. Rank hold ARNA as of Q2 2018.

  • Avantax Planning Partners reported no remaining Arena Pharmaceuticals Inc position as of Q2 2018 after selling out during the quarter.
  • Avantax Planning Partners sold 1,000 Arena Pharmaceuticals Inc shares in Q2 2018, an estimated $40K.
  • Avantax Planning Partners first reported a position in Arena Pharmaceuticals Inc in Q4 2016 and held it in 3 quarters.
  • Avantax Planning Partners's Arena Pharmaceuticals Inc position peaked at $40K in Q1 2018.
  • 165 funds tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q2 2018.

Based on Avantax Planning Partners's 13F filing for Q2 2018, filed 13 Aug 2018.